Institution
Tata Memorial Hospital
Healthcare•Mumbai, India•
About: Tata Memorial Hospital is a healthcare organization based out in Mumbai, India. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 3187 authors who have published 4636 publications receiving 109143 citations.
Topics: Cancer, Breast cancer, Population, Radiation therapy, Carcinoma
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Standard first-line therapy for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an EGFR-directed oral TKI, but whether adding pemetrexed-carboplatin to Oral TKI treatment with EGFR antagonists is evaluated.
Abstract: 9001Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed-carboplatin to oral TKI ...
27 citations
••
27 citations
••
TL;DR: Retrospective analysis of male urethral carcinoma is carried out to assess the best therapeutic approach to the management of this tumor.
Abstract: Aim: Retrospective analysis of male urethral carcinoma to assess the best therapeutic approach to the management of this tumor.
Methods: A review of 36 cases of male urethral carcinoma diagnosed and treated at our center was performed. Clinical features, treatment modality and outcomes were analysed.
Results: The overall median survival time was 55.16 months. The 5-year overall and disease-free survival rate for the cohort was 49% and 23%, respectively. The 5-year survival is 67% for low-stage versus 33% for high-stage tumors and is significantly different (P = 0.001). The survival was 72% for tumors of the distal urethra versus 36% for tumors of the proximal, with a P-value of 0.02.
Conclusion: The tumor location and clinicopathological stage were the most important predictors of the disease-free and overall survival. Multimodal approach is necessary for achieving local control especially for proximal and higher stage tumors.
27 citations
••
TL;DR: The use of a THER in the treatment of malignant tumours of bone is oncologically safe; it gives consistent and predictable results with low rates of complication.
Abstract: Rarely, the extent of a malignant bone tumour may necessitate resection of the complete humerus to achieve adequate oncological clearance. We present our experience with reconstruction in such cases using a total humeral endoprosthesis (THER) in 20 patients (12 male and eight female) with a mean age of 22 years (6 to 59). We assessed the complications, the oncological and functional outcomes and implant survival. Surgery was performed between June 2001 and October 2009. The diagnosis included osteosarcoma in nine, Ewing’s sarcoma in eight and chondrosarcoma in three. One patient was lost to follow-up. The mean follow-up was 41 months (10 to 120) for all patients and 56 months (25 to 120) in survivors. There were five local recurrences (26.3%) and 11 patients were alive at time of last follow-up, with overall survival for all patients being 52% (95% confidence interval (CI) 23.8 to 74) at five years. The mean Musculoskeletal Tumor Society score for the survivors was 22 (73%; 16 to 23). The implant survival was 95% (95% CI 69.5 to 99.3) at five years.
The use of a THER in the treatment of malignant tumours of bone is oncologically safe; it gives consistent and predictable results with low rates of complication.
27 citations
••
27 citations
Authors
Showing all 3213 results
Name | H-index | Papers | Citations |
---|---|---|---|
Al B. Benson | 113 | 578 | 48364 |
Keitaro Matsuo | 97 | 818 | 37349 |
Ashish K. Jha | 87 | 503 | 30020 |
Noopur Raje | 82 | 506 | 27878 |
Muthupandian Ashokkumar | 76 | 511 | 20771 |
Snehal G. Patel | 73 | 367 | 16905 |
Rainu Kaushal | 58 | 232 | 16794 |
Ajit S. Puri | 54 | 369 | 9948 |
Jasbir S. Arora | 51 | 351 | 15696 |
Sudeep Sarkar | 48 | 273 | 10087 |
Ian T. Magrath | 47 | 107 | 8084 |
Pankaj Chaturvedi | 45 | 325 | 15871 |
Pradeep Kumar Gupta | 44 | 416 | 7181 |
Shiv K. Gupta | 43 | 150 | 8911 |
Kikkeri N. Naresh | 43 | 245 | 6264 |